| Literature DB >> 31867052 |
Yiyu Qi1,2,3, Qichun Zhang1,2,3,4, Huaxu Zhu1,2,3.
Abstract
Huang-Lian Jie-Du decoction (HLJDD), a famous traditional Chinese prescription constituted by Rhizoma Coptidis, Radix Scutellariae, Cortex Phellodendri and Fructus Gradeniae, has notable characteristics of dissipating heat and detoxification, interfering with tumors, hepatic diseases, metabolic disorders, inflammatory or allergic processes, cerebral diseases and microbial infections. Based on the wide clinical applications, accumulating investigations about HLJDD focused on several aspects: (1) chemical analysis to explore the underlying substrates responsible for the therapeutic effects; (2) further determination of pharmacological actions and the possible mechanisms of the whole prescription and of those representative ingredients to provide scientific evidence for traditional clinical applications and to demonstrate the intriguing molecular targets for specific pathological processes; (3) pharmacokinetic feature studies of single or all components of HLJDD to reveal the chemical basis and synergistic actions contributing to the pharmacological and clinically therapeutic effects. In this review, we summarized the main achievements of phytochemical, pharmacological and pharmacokinetic profiles of HLJDD and its herbal or pharmacologically active chemicals, as well as our understanding which further reveals the significance of HLJDD clinically.Entities:
Keywords: Huang-Lian Jie-Du decoction; Parmacological; Pharmacokinetic; Phytochemical; Traditional Chinese medicine
Year: 2019 PMID: 31867052 PMCID: PMC6918586 DOI: 10.1186/s13020-019-0277-2
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1Appearance and processing technology of Huang-Lian Jie-Du concentrated pill
Fig. 2Structures of representative alkaloids isolated from HLJDD
Fig. 3Structures of representative flavonoids isolated from HLJDD
Fig. 4Structures of representative iridoid glycosides isolated from HLJDD
Pharmacological actions and therapeutic or regulatory mechanisms of HLJDD
| Pharmacological actions | Model | Mechanisms | Refs. |
|---|---|---|---|
| Anti-tumor | Hepatocellular carcinoma xenograft murine | Suppressing xenografted growth by inactivating eEF2 through the activation of AMPK signaling | [ |
Hepatocellular carcinoma xenograft Hep G2 PLC/PRF/5 | Inducing apoptosis Blocking cell cycle progression by regulating cell-cycle-related factor (p21/WAF1, cyclin B1, cyclin A, Cdc25C, and Cdc2) Promoting programmed cell death by modulating Bcl-2 Triggering mitochondrial pathway through membrane depolarization and caspase-9 activation Inhibiting NF-κB survival signaling pathway | [ | |
| Hepatoprotection | Thioacetamide | Restoring redox system, gut flora, and urea cycle | [ |
| Bile duct ligation | Restoring redox system, gut flora, Kreb’s cycle, and oxidation of branchedchain amino acids | [ | |
| Bile duct ligation | Ameliorating energy metabolism, amino acid metabolism and gut microbiota metabolism Protecting oxidative injury | [ | |
| Anti-inflammatory | Carrageenan-induced rat air pouch A23187-stimulated peritoneal macrophages LPS-stimulated RAW 264.7 macrophages | Inhibiting inflammatory responses and eicosanoids generation from different lipoxygenases | [ |
Carrageenan-induced mice paw edema LPS-stimulated RAW 264.7 macrophages | Reducing oxidative injury | [ | |
| Collagen-induced arthritis rats | Regulating fatty acid oxidation and arachidonic acid metabolism | [ | |
| LPS-stimulated RAW 264.7 macrophages | Suppressing the production of inflammatory mediators via inactivation of NF-κB and MAPKs, and degradation of IκBα | [ | |
| Cecal ligation and puncture-induced septic model rats | Enhancing cholinergic anti-inflammatory pathway Inhibiting HMGB-1/TLR4/NF-κB signaling pathway | [ | |
| Cecal ligation and puncture-induced septic model rats | Suppressing the production of proinflammatory cytokines Reversing the shift from Th1 to Th2 response and promote Th1/Th2 balance toward Th1 predominance Iinhibiting Th17 activation | [ | |
2,4-dinitrochlorobenzene-induced atopic dermatitis mice LPS-stimulated RAW 264.7 macrophages | Inhibiting MAPKs/NF-κB pathway | [ | |
| LPS-induced gingivitis rats | Inhibiting AMPK and ERK1/2 pathway | [ | |
| LPS-induced acute kidney injury mice | Inhibiting NF-κB and MAPK activation Activating Akt/HO-1 pathway Ameliorating disturbances in oxidative stress and energy metabolism | [ | |
| Anti-allergy | Antigen-induced RBL-2H3 cells | Suppressing allergic mediators via inactivation of MAPKs and Lyn pathway | [ |
| Modulation of blood lipid | ApoE(-/-) mice Primary bone marrow-derived macrophage Foam cells | Regulating the functional differentiation of monocytes, macrophages, and foam cells | [ |
| High-fat diet-induced hyperlipidemia rats | Activating the activityof lipid metabolism enzyme Enhancing the expressions of LDLR and PPAR γ mRNAs | [ | |
| High-fat diet and streptozotocin-induced T2DM rats | Inhibiting the activity of intestinal pancreatic lipase | [ | |
| Modulation of blood glucose | streptozotocin-induced T2DM rats | Enhancing GLP-1 secretion in gut to promoting insulin secretion and improving function of β cell | [ |
Min6 cells NCI-H716 cells | Elevating intracellular cAMP levels to promote GLP-1 secretion and insulin secretion Increasing β cell mass through hyperplasia and hypertrophy | [ | |
| Central nervous system diseases | MCAO rats | Inhibiting neuron apoptosis and enhancing its proliferation through activating PI3K/Akt signaling pathway and HIF-1α | [ |
| MCAO rats | Inducing protective autophagy through the regulation of MAPK signals | [ | |
| MCAO rats | Ameliorating the disordered metabolisms in energy, membrane and mitochondrial, amino acid and neurotransmitter Alleviating the inflammatory damage and the oxidative stress from ROS Recovering the destructed osmoregulation | [ | |
| SAMP8 | Modulating gene expressions in signal transduction (Dusp12, Rps6ka1, Rab26, Penk1, Nope, Leng8, Syde1, Phb, Def8, Ihpk1, Tac2, Pik3c2a), protein metabolism (Ttc3, Amfr, Prr6, Ube2d2), cell growth and development (Ngrn, Anln, Dip3b, Acrbp), nucleic acid metabolism (Fhit, Itm2c, Cstf2t, Ddx3x, Ercc5, Pcgfr6), energy metabolism (Stub1, Uqcr, Nsf), immune response (C1qb), regulation of transcription (D1ertd161e, Gcn5l2, Ssu72), transporter (Slc17a7, mt-Co1), nervous system development (Trim3), and neurogila cell differentiation (Tspan2) | [ | |
| APPswe/PS1dE9 mice | Ameliorating neuroinflammation and sphingolipid metabolic disorder | [ | |
| HEK 293 cells | Inhibiting indoleamine 2,3-dioxygenase activity | [ | |
| Anti-infection | Inhibiting formation of hyphae and colony morphologies through downregulating the expression of HWP1, ALS3, UME6 and CSH1 | [ | |
| Reducing pyocyanin pigment, elastolytic activity, proteolytic activity, biofilm formation, and bacterial motility | [ | ||
| H1N1 | Inhibiting NA activity | [ | |
| Modulation of microbiota | High-fat diet and streptozotocin-induced T2DM rats | Ameliorating hyperglycemia and restoring the disturbed gut microbiota structure and function through increasing short chain fatty acids-producing bacteria while reducing conditioned pathogenic bacteria | [ |
Fig. 5Molecular mechanisms of anti-tumor effect of HLJDD
Fig. 6Molecular mechanisms of anti-inflammatory effect of HLJDD
Fig. 7Molecular mechanism of HHLJDD in treating CNS diseases